SG10201801905WA - A combination therapy for a stable and long term engraftment - Google Patents
A combination therapy for a stable and long term engraftmentInfo
- Publication number
- SG10201801905WA SG10201801905WA SG10201801905WA SG10201801905WA SG10201801905WA SG 10201801905W A SG10201801905W A SG 10201801905WA SG 10201801905W A SG10201801905W A SG 10201801905WA SG 10201801905W A SG10201801905W A SG 10201801905WA SG 10201801905W A SG10201801905W A SG 10201801905WA
- Authority
- SG
- Singapore
- Prior art keywords
- stable
- long term
- combination therapy
- term engraftment
- engraftment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578917P | 2011-12-22 | 2011-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201801905WA true SG10201801905WA (en) | 2018-04-27 |
Family
ID=48669650
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201801905WA SG10201801905WA (en) | 2011-12-22 | 2012-12-20 | A combination therapy for a stable and long term engraftment |
| SG11201403459XA SG11201403459XA (en) | 2011-12-22 | 2012-12-20 | A combination therapy for a stable and long term engraftment |
| SG11201403456UA SG11201403456UA (en) | 2011-12-22 | 2012-12-20 | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201403459XA SG11201403459XA (en) | 2011-12-22 | 2012-12-20 | A combination therapy for a stable and long term engraftment |
| SG11201403456UA SG11201403456UA (en) | 2011-12-22 | 2012-12-20 | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |
Country Status (16)
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140212398A1 (en) | 2011-09-08 | 2014-07-31 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| KR20140102730A (ko) | 2011-12-08 | 2014-08-22 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 포유류 태아 폐 세포와 이를 치료용으로 사용하는 방법 |
| SG10201801905WA (en) | 2011-12-22 | 2018-04-27 | Yeda Res & Dev | A combination therapy for a stable and long term engraftment |
| EP2996698A2 (en) | 2013-05-09 | 2016-03-23 | Advanced Neuroregenerative Therapies LLC | G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal |
| US10668109B2 (en) | 2015-06-18 | 2020-06-02 | Yeda Research And Development Co. Ltd. | Conditioning protocols and use of same for tissue regeneration |
| CN108135938A (zh) | 2015-07-16 | 2018-06-08 | 耶达研究及发展有限公司 | 基因修饰的抗第三方中央型记忆t细胞及其在免疫疗法中的用途 |
| EP4458953A3 (en) * | 2015-08-25 | 2025-01-22 | The UAB Research Foundation | Methods for stem cell transplantation |
| CA3005767A1 (en) * | 2015-12-04 | 2017-06-08 | Fred Hutchinson Cancer Research Center | Uses of expanded populations of hematopoietic stem/progenitor cells |
| CN109475581A (zh) * | 2016-05-22 | 2019-03-15 | 耶达研究及发展有限公司 | 为了移植及诱导耐受性而使用肺细胞的方法 |
| JP2019517518A (ja) * | 2016-06-03 | 2019-06-24 | メモリアル スローン ケタリング キャンサー センター | 早期治療選択肢としての養子細胞療法 |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| EP3571295A1 (en) | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
| AU2018209452B2 (en) | 2017-01-20 | 2024-11-07 | Heidelberg Pharma Research Gmbh | Compositions and methods for the depletion of CD137+ cells |
| ES2977897T3 (es) | 2017-03-15 | 2024-09-02 | Orca Biosystems Inc | Composiciones y métodos para trasplantes de células madre hematopoyéticas |
| AU2018367546B2 (en) * | 2017-11-15 | 2024-07-18 | Weird Science Llc | Methods and compositions for non-myeloablative bone marrow reconstitution |
| EA202090947A1 (ru) | 2017-11-29 | 2020-08-26 | Маджента Терапьютикс, Инк. | Композиции и способы для истощения cd5+ клеток |
| EP3723785A1 (en) * | 2017-12-17 | 2020-10-21 | Yeda Research and Development Co. Ltd | Cop9 signalosome (csn) complex modulators and uses thereof |
| PL3749334T3 (pl) | 2018-02-08 | 2025-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Allogeniczne przeszczepienie krwiotwórczych komórek macierzystych |
| WO2019178106A1 (en) * | 2018-03-12 | 2019-09-19 | Medeor Therapeutics, Inc. | Methods for treating non-cancerous disorders using hematopoietic cells |
| US10881692B2 (en) | 2018-04-05 | 2021-01-05 | Medeor Therapeutics, Inc. | Compositions for establishing mixed chimerism and methods of manufacture thereof |
| US10842821B2 (en) | 2018-04-05 | 2020-11-24 | Medeor Therapeutics, Inc. | Cellular compositions derived from prior organ donors and methods of manufacture and use thereof |
| WO2020023561A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| US11435350B2 (en) | 2018-09-18 | 2022-09-06 | Medeor Therapeutics, Inc. | Methods of analysis of blood from deceased donors |
| US11813376B2 (en) | 2018-09-18 | 2023-11-14 | Medeor Therapeutics, Inc. | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof |
| WO2020061180A1 (en) * | 2018-09-18 | 2020-03-26 | Medeor Therapeutics, Inc. | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof |
| CA3114292A1 (en) * | 2018-09-27 | 2020-04-02 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
| WO2020091797A1 (en) * | 2018-11-01 | 2020-05-07 | Children's Hospital Medical Center | Reduced intensity conditioning with melphalan |
| CN109781987B (zh) * | 2019-01-09 | 2022-04-26 | 暨南大学 | 终末效应t细胞亚群在制备辅助评估再生障碍性贫血病情程度试剂盒中的应用 |
| US20220195414A1 (en) * | 2019-04-08 | 2022-06-23 | Russell Biotech, Inc. | Improved Manufacturing Procedures for Cell Based Therapies |
| MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| RU2723164C1 (ru) * | 2019-10-07 | 2020-06-09 | Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" | Способ расчета дозы клеток-предшественниц гемопоэза в лейкоцитаферезном продукте путем учета изменения целостности клеточных мембран при хранении |
| AU2020379319A1 (en) * | 2019-11-05 | 2022-06-23 | Yeda Research And Development Co. Ltd. | Use of veto cells in treatment of T cell mediated autoimmune diseases |
| CA3180451A1 (en) * | 2020-05-28 | 2021-12-02 | Biomagnetic Solutions Llc | Compositions and methods for negative selection of naive t and b cells with a single antibody |
| WO2022133282A1 (en) * | 2020-12-18 | 2022-06-23 | Ossium Health, Inc. | Methods of cell therapies |
| CN112669992B (zh) * | 2020-12-30 | 2024-06-11 | 中国人民解放军总医院 | 单倍体造血干细胞移植atg个体化用药量的计算方法 |
| RU2764742C1 (ru) * | 2021-04-09 | 2022-01-20 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТИО им. академика В.И. Шумакова" Минздрава России) | Способ подбора режима иммуносупрессии детям раннего возраста в отдаленном периоде после трансплантации печени |
| US20250114360A1 (en) * | 2022-02-03 | 2025-04-10 | The Regents Of The University Of California | Novel regimen for augmenting and extending transplant tolerance |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5635156A (en) | 1993-09-13 | 1997-06-03 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US6217867B1 (en) | 1993-09-13 | 2001-04-17 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US20010009663A1 (en) | 1993-09-13 | 2001-07-26 | Suzanne T. Ildstad | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| US5514364A (en) | 1993-09-13 | 1996-05-07 | University Of Pittsburgh | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| IL107483A0 (en) | 1993-11-03 | 1994-02-27 | Yeda Res & Dev | Bone marrow transplantation |
| IL112969A (en) * | 1994-03-17 | 2001-05-20 | Baxter Int | Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator |
| JP2002514193A (ja) * | 1996-11-15 | 2002-05-14 | バクスター、インターナショナル、インコーポレイテッド | 同種幹細胞移植のためのコンディショニング |
| US6039684A (en) | 1997-12-11 | 2000-03-21 | Allegheny University Of The Health Sciences | Non-lethal conditioning methods for the treatment of acquired immunodeficiency syndrome |
| ATE439137T1 (de) * | 1997-11-14 | 2009-08-15 | Gen Hospital Corp | Behandlung von hämatologischen störungen |
| AU2003204277B2 (en) | 1997-11-14 | 2006-03-16 | The General Hospital Corporation | Treatment of hematologic disorders |
| WO1999058977A1 (en) | 1998-05-11 | 1999-11-18 | Miltenyi Biotec Gmbh | Method of direct selection of antigen-specific t cells |
| CA2279474C (en) | 1998-07-31 | 2011-01-04 | Stemcell Technologies Inc. | Novel antibody composition for debulking blood and bone marrow samples from cml patients |
| AU2002239424A1 (en) | 2000-11-14 | 2002-05-27 | The University Of Louisville Research Foundation, Inc. | Methods for enhancing engraftment of purified hematopoietic stem cells in allogeneic recipients |
| WO2002040640A2 (en) | 2000-11-14 | 2002-05-23 | The University Of Louisville Research Foundation, Inc. | Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc) |
| WO2002040050A1 (en) | 2000-11-14 | 2002-05-23 | The University Of Louisville Research Foundation, Inc. | Non-lethal methods for conditioning a recipient for bone marrow transplantation |
| AU2002309703A1 (en) | 2001-05-09 | 2002-11-18 | The University Of Louisville Research Foundation, Inc. | Hematopoietic stem cell chimerism to treat autoimmune disease |
| AU2002322857A1 (en) | 2001-08-01 | 2003-02-17 | Jewish Hospital Healthcare Services, Inc. | Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd |
| US20070141027A1 (en) | 2003-05-28 | 2007-06-21 | University Of Louisville Research Foundation Inc. | Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation |
| US20070098693A1 (en) | 2003-05-28 | 2007-05-03 | Ildstad Suzanne T | Methods for enhancing engraftment of purified hematopoietic stem cells in allogenic recipients |
| WO2009094456A2 (en) * | 2008-01-22 | 2009-07-30 | Johns Hopkins University | Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection |
| US8632768B2 (en) | 2008-05-30 | 2014-01-21 | University Of Louisville Research Foundation, Inc. | Human facilitating cells |
| DE102009040716B4 (de) * | 2009-09-10 | 2011-07-14 | Miltenyi Biotec GmbH, 51429 | Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen |
| SG10201801905WA (en) | 2011-12-22 | 2018-04-27 | Yeda Res & Dev | A combination therapy for a stable and long term engraftment |
| US20210045900A1 (en) | 2019-08-13 | 2021-02-18 | Stryker Corporation | Stent braid pattern with enhanced radiopacity |
-
2012
- 2012-12-20 SG SG10201801905WA patent/SG10201801905WA/en unknown
- 2012-12-20 RU RU2014128479A patent/RU2657758C2/ru active
- 2012-12-20 DK DK12861023.5T patent/DK2797421T3/da active
- 2012-12-20 IN IN1468MUN2014 patent/IN2014MN01468A/en unknown
- 2012-12-20 EP EP12859036.1A patent/EP2793914B1/en active Active
- 2012-12-20 RU RU2014129632A patent/RU2648354C2/ru active
- 2012-12-20 WO PCT/IL2012/050542 patent/WO2013093920A2/en not_active Application Discontinuation
- 2012-12-20 BR BR112014015960A patent/BR112014015960A8/pt not_active IP Right Cessation
- 2012-12-20 SG SG11201403459XA patent/SG11201403459XA/en unknown
- 2012-12-20 MX MX2014007648A patent/MX2014007648A/es active IP Right Grant
- 2012-12-20 US US14/367,923 patent/US10434121B2/en active Active
- 2012-12-20 SG SG11201403456UA patent/SG11201403456UA/en unknown
- 2012-12-20 MX MX2014007647A patent/MX370404B/es active IP Right Grant
- 2012-12-20 EP EP12861023.5A patent/EP2797421B1/en active Active
- 2012-12-20 DK DK12859036.1T patent/DK2793914T3/da active
- 2012-12-20 CA CA2859952A patent/CA2859952C/en active Active
- 2012-12-20 US US14/367,917 patent/US10369172B2/en active Active
- 2012-12-20 AU AU2012355989A patent/AU2012355989B2/en not_active Ceased
- 2012-12-20 JP JP2014548337A patent/JP2015504047A/ja active Pending
- 2012-12-20 AU AU2012355990A patent/AU2012355990B2/en not_active Ceased
- 2012-12-20 KR KR1020147020449A patent/KR102109643B1/ko active Active
- 2012-12-20 BR BR112014015959A patent/BR112014015959A8/pt active Search and Examination
- 2012-12-20 IN IN1467MUN2014 patent/IN2014MN01467A/en unknown
- 2012-12-20 CN CN201280068202.9A patent/CN104470542A/zh active Pending
- 2012-12-20 KR KR1020147020448A patent/KR20140105848A/ko not_active Withdrawn
- 2012-12-20 WO PCT/IL2012/050541 patent/WO2013093919A2/en not_active Application Discontinuation
- 2012-12-20 JP JP2014548336A patent/JP6313219B2/ja active Active
- 2012-12-20 ES ES12859036T patent/ES2864323T3/es active Active
- 2012-12-20 CN CN201280068917.4A patent/CN104093314A/zh active Pending
- 2012-12-20 CA CA2859953A patent/CA2859953A1/en not_active Abandoned
- 2012-12-20 ES ES12861023T patent/ES2811529T3/es active Active
-
2014
- 2014-07-11 ZA ZA2014/05071A patent/ZA201405071B/en unknown
- 2014-07-18 ZA ZA2014/05298A patent/ZA201405298B/en unknown
-
2016
- 2016-11-18 AU AU2016259415A patent/AU2016259415B2/en not_active Ceased
-
2018
- 2018-01-22 JP JP2018007779A patent/JP2018080201A/ja active Pending
-
2019
- 2019-07-11 US US16/508,325 patent/US11497776B2/en active Active
- 2019-08-13 US US16/538,954 patent/US11504399B2/en active Active
-
2022
- 2022-10-02 US US17/958,401 patent/US20230039904A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405071B (en) | A combination therapy for a stable and long term engraftment | |
| ZA201305897B (en) | Combination therapy | |
| GB201015905D0 (en) | Autoinjectors | |
| GB2486690B (en) | Autoinjectors | |
| GB201021717D0 (en) | Autoinjectors | |
| GB201106803D0 (en) | Sonodynamic therapy | |
| ZA201400120B (en) | Combination therapy | |
| GB201114212D0 (en) | Therapeutic agents | |
| GB201119401D0 (en) | Therapeutic agents | |
| EP2724735A4 (en) | DRUG SUPPLY | |
| PL2723330T3 (pl) | Lek kombinowany zawierający środek naczynioskurczowy | |
| ZA201400435B (en) | Therapeutic methods | |
| EP2701744A4 (en) | COMBINATION THERAPY | |
| GB2486681B (en) | Autoinjectors | |
| IL232239A0 (en) | Medical use | |
| GB201021716D0 (en) | Autoinjectors | |
| IL233303B (en) | Combined treatment for stable and prolonged transplantation | |
| GB201114226D0 (en) | Combination therapy | |
| GB201110895D0 (en) | Therapeutic use | |
| GB201121907D0 (en) | A coffin | |
| GB201115558D0 (en) | Therapeutic agents | |
| GB201110614D0 (en) | Therapeutic agents | |
| GB201102694D0 (en) | Laser therapy | |
| GB201102236D0 (en) | Inventions and therapy | |
| GB201102239D0 (en) | Inventions and therapy |